Oslo, October 28th, 2025 - In the third quarter 2025, Navamedic ASA (OSE: NAVA),
a Nordic pharma company and trusted supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies, delivered
revenues of NOK 138.9 million, a 12.9% increase from the third quarter in 2024.
Gross margin improved to 37.5 per cent, compared to 37.1 per cent in Q3 2024 and
Adjusted EBITDA amounted to NOK 11.3 million compared to NOK 8.6 million in
2024.
The overall revenues performance was driven by increases in all three business
areas and the Rx business area included 10.6MNOK in revenues from the dne
business.
The acquisition of the dne pharma business was completed in July, with a
subsequent successful rights issue completed in October.
"We are excited about the acquisition of the dne pharma business. The portfolio
of products we have acquired fits well into the Navamedic setup and provides a
new focus area with growth potential, Addiction, within our Rx portfolio.
Further to this, addiction is a growing societal challenge and Navamedic is now
in a position to be at the forefront of treatment within this category," said
Kathrine Gamborg Andreassen, CEO of Navamedic.
Additional Q3 key figures
Operating costs ended at NOK 40.8 million, compared to NOK 37.1 million last
year. Operating results (EBIT) for the second quarter of 2025 amounted to
negative NOK 0.2 million, mostly due to the amortization of the intangible
assets acquired through the dne transaction. Net financial items ended at
negative NOK 3.6 million and profit before tax was negative NOK 3.8 million. The
total cash flow for the quarter was positive NOK 9.1 million and the cash
balance at the end of the quarter was NOK 51.7 million.
Outlook
Navamedic continues to see growth and new expansion opportunities and reiterates
its mid-term ambition of building a NOK 1 billion revenue company.
"The third quarter was marked by the acquisition of the dne business and growth
across our three business areas. The acquired portfolio of products with growth
potential within the addiction treatment area, combined with the antibiotics
portfolio, the Parkinsons disease product Flexilev in Orafid and Navamedic's
other hero brands, sets Navamedic up for growth going forward towards the
ambition of reaching NOK 1 billion in revenues," Andreassen concluded.
Presentation
Navamedic will present the results for the third quarter of 2025 at 08.30 today.
CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the
presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be
webcast at the following link:
https://navamedic.com/investors/financial-results/
Note: EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section in the
attached presentation.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives. What sets us apart
is our deep-rooted commitment to understanding the needs and requirements of the
countries where we are present. Our local insight and competence enable us to
understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.
For more information, please visit Navamedic.com.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.